Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
65 lessons
11mFollistatin 344 is sold online as a muscle-building peptide. It is not a peptide: at 344 amino acids it is a protein. No published human trial has tested the injected product, the only follistatin-based drug to reach randomized trials grew muscle without improving function, and lab testing of black-market vials found most of them were not what the label said.
10mGonadorelin is a lab-made copy of GnRH, the brain hormone that starts the testosterone and fertility chain. Both US human products were discontinued, current US labels are for cattle, and no published trial has tested it for protecting fertility on testosterone therapy.
11mOn November 9, 2026, FDA required a class-wide warning about NAION, a rare optic nerve condition that can cause sudden vision loss. The risk is real enough to label, small in absolute terms, and still debated. Here is the evidence, drug by drug.
10mTwo antibodies that block the myostatin/activin pathway are being tested alongside GLP-1 drugs to protect lean mass. Bimagrumab's phase 2 BELIEVE trial is published in Nature Medicine. Apitegromab is FDA-approved, but only for spinal muscular atrophy. Neither is a peptide or a pill.
7mCT-G32, also called SCO-940, is a preclinical four-receptor obesity candidate. The sponsors reported rat and monkey data at TIDES Europe in November 2026 and plan a US IND in February 2027. Here's how to place that news on the drug-development ladder.
9mNAD+ is essential to cells. That does not make every NAD+ treatment effective. A practical guide to IV claims, oral precursors and what human studies actually measured.
9mGHK-Cu is a small copper-binding peptide with decades of lab research and a thin human record. Here's what it is, why topical and injectable use are different questions, and where FDA stands in 2026.
10mThe collagen powder in a grocery store and the vial labeled "research use only" share one word and almost nothing else. This guide explains what each one is, how each is regulated, what the human evidence shows for collagen on skin, joints and bone, and where the copper peptide GHK-Cu fits.
7mThe question arrives at the front desk first. Here is a three-tier script that answers it honestly, cites what exists, and never turns into a claim or a referral to a vendor.
8mEnamel matrix derivative and rhPDGF-BB are FDA-approved devices with decades of trials. BPC-157 and TB-500 have one rat study each in periodontitis. Here is the whole picture, with sources.
12mA goal-by-goal map of the peptides people ask about most, scored on human evidence and regulatory status. The only ones with strong evidence are approved drugs; most of the rest are animal data. No vendors, no dosing.
11mNo peptide is FDA-approved for building muscle in healthy adults. Here is what the human trials actually measured for growth hormone secretagogues, IGF-1 analogs, MOTS-c and the GLP-1 drugs, where each sits on the evidence ladder, and what regulators and anti-doping rules say.
6mWhat Cartalax (Ala-Glu-Asp, T-31) is, where its cartilage and anti-aging claims come from, what cell and rat studies found, and the missing human data.
8mSearching for a KLOW peptide dosage and frequency chart? Here's the blend math by label, how frequency discussions online differ from evidence, and how to log a four-component vial — without dosing advice.
10mSS-31 is elamipretide, a mitochondria-targeting peptide. FDA approved it in 2025 as Forzinity for one rare disease. Trials in other conditions mostly missed their main goals, and research vials are not the approved drug.
6mAdamax is marketed as a modified Semax. Semax has decades of mostly Russian research. Adamax has essentially none in the published literature. Here's the honest comparison.
8mGLOW is a three-peptide blend: BPC-157, TB-500 and GHK-Cu. Here's what's in a vial, how much of each component is in every draw, how it differs from KLOW and Wolverine, and what the evidence does and doesn't show.
8m"Wolverine" is a nickname for BPC-157 plus TB-500. Here's what's in the blend, how the vial math works, how it compares with GLOW and KLOW, and how thin the human evidence still is.
7mThe panel backed six peptide nominations but not Emideltide. Here is why evidence and identity questions mattered, and what the result means for people following sleep peptides.
7mEpitalon received a narrow advisory vote for 503A compounding in insomnia. That vote is not FDA approval, immediate access, or validation of longevity claims.
7mA beginner-friendly guide to KPV, its relationship to alpha-MSH, the evidence behind its nominated uses, and the limits of the 2026 PCAC recommendation.
7mMOTS-c now has a favorable advisory recommendation. It still does not have FDA drug approval or an open 503A compounding path.
7mThe favorable Semax vote moved its compounding nomination forward, but the narrow result exposed unresolved questions about evidence, characterization, and US clinical use.
8mBPC-157 is still a research compound, but the advisory review makes one thing clear: access, sourcing, and evidence quality now matter as much as the mechanism.
10mThe latest sports medicine review is useful because it separates promising recovery biology from the human evidence gap and the antidoping risks.
8mA 2025 review makes the same point the peptide world keeps avoiding: some compounds have real human data, and many popular names still do not.
8mThe regulatory story matters because it changes what you can trust, what you should track, and why supply chain quality now sits beside mechanism in the BPC-157 debate.
9mThe GH-IGF1 axis keeps showing up in peptide medicine because it links visceral fat, recovery, and lean mass. The trick is separating the clinical signal from the wellness noise.
8mBPC-157 has a real research footprint, but most of the confidence in the compound still comes from preclinical work. That gap matters when people start talking about safety like the answer is settled.
9mThe new BPC-157 review is useful because it separates mechanism from marketing. The peptide looks biologically interesting, but the human evidence is still thin.
Pet owners are hearing more about BPC-157 and TB-500 for recovery. This guide separates the real biology from the social-media hype and shows what actually matters for healing.
8mRegulation does not settle the peptide debate by itself. It forces clearer questions about sourcing, safety, evidence, and who is responsible when claims move faster than data.
9mHealthy aging is not a slogan. It is a measurable question about inflammation, tissue repair, metabolic control, and whether a peptide has human data behind it.
10mOrthopaedics is paying closer attention to peptides because the field keeps running into the same problem: recovery is biology, but biology still needs evidence before it becomes a protocol.
9mSports medicine keeps pulling peptides into the conversation because recovery pressure is real. The hard part is separating promising biology from weak evidence, gray-market hype, and antidoping risk.
9mClinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.
8mMOTS-c is showing up in cardiac stress research. A new rat-heart study points toward mitochondrial bioenergetics, mtDNA integrity, and post-ischemic recovery.
8mMOTS-c is being studied beyond energy and metabolism. New research points toward tissue-stress biology, lysosomal stability, and cell survival under ischemic pressure.
8mGLP-1 research is moving beyond weight loss. New breast cancer risk and survival signals are interesting, but they need careful interpretation.
8mPeptide research is moving fast. Here is how to read the evidence before turning a headline, mechanism, or social post into a protocol.
8mNew 2026 data puts BPC-157 into a sharper recovery frame: oxidative stress, inflammation, apoptosis, angiogenesis, and the limits of animal evidence.
8mGLP-1 research is moving beyond weight loss. Recent ophthalmology studies suggest possible links with age-related macular degeneration, but the signals are mixed and need careful interpretation.
GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.
7mThe biggest peptide trend in 2026 may not be a molecule. It may be oversight, sourcing quality, and the ability to separate evidence from marketing.
8mGLP-1 receptor agonists cause nausea in up to 44% of users and it is the top reason for discontinuation. Here is what the research shows about BPC-157 as a potential gut protectant, and where the evidence stops.
9mWeight regain after stopping GLP-1 treatment is common in trials. Understand the evidence, the numbers, and the questions that make a maintenance conversation useful.
7mAMA and FDA updates make one thing clear: peptide interest is moving faster than human evidence, dosing standards, and product-quality controls. Use this checklist before trusting a vial.
8mStack stories spread fast because they are visual and emotional. The smarter move is not to copy the protocol. It is to ask better evidence questions.
8mBPC-157 finally has a registered human sports-injury study. The signal is important, but it is not proof yet. Here is how to read the trial without the hype.
8mA new ECRI and ISMP warning says popular wellness peptides are being marketed faster than the evidence can support. Here is how to separate compound science from product risk.
8mA new sports medicine review puts injury-recovery peptides in context. Some mechanisms are promising, but human evidence, safety data, and regulatory status still matter.
9mFood thoughts, hunger and weight are different outcomes. Learn what human studies show about GLP-1 treatment and what returning food noise can—and cannot—tell you.
9mPsoriasis affects 125 million people worldwide. While peptides aren't a cure, emerging research suggests certain compounds may help calm inflammation and support skin repair. Here's what the science says.
10mEpitalon is a lab-made four-amino-acid peptide based on a pineal gland extract. It lengthens telomeres in cell studies, but human evidence is small and old. It is not FDA approved, and since October 2026 it is one of six peptides in an HHS compounding policy.
9mTwo products share the CJC-1295 name. Learn what the Drug Affinity Complex changes, what the 2006 human studies actually measured, and why the no-DAC version has far less published evidence.
10mBPC-157 and TB-500 are the two most evidence-backed peptides for structural tissue repair. For herniated disc recovery, they work through complementary pathways — here's how to stack them, dose them, and phase in the rest of a recovery protocol.
11mIGF-1 LR3 is a lab-modified copy of the IGF-1 hormone, built in 1992 as a research reagent. A 2026 review places it in the tier with no peer-reviewed human studies at all. It is not FDA approved, is regulated as a biologic rather than a peptide, and is prohibited in sport.
8mIGF-1 LR3 and HGH are often grouped together, but they act at different points in the GH/IGF-1 axis. Here is the protocol-level breakdown for clinicians, athletes, and longevity-focused users.
11mBPC-157 activates multiple tissue repair pathways simultaneously. Users report faster recovery from injury, improved gut healing, enhanced joint mobility—backed by published clinical data.
9mMOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It has strong mouse data, one recruiting placebo-controlled human trial and no FDA approval. In October 2026 HHS added it to an interim compounding policy.
9mBPC-157 accelerates tissue repair by stimulating angiogenesis and collagen synthesis. Here's what the research shows and what users need to know.
9mRetatrutide is often marketed as muscle-sparing. The published scans tell a narrower story: mostly fat loss, some lean loss, and no head-to-head body-composition data against tirzepatide yet.
12mBPC-157 shows promise in clinical research for accelerating tendon repair and recovery. Learn how this peptide works and what the science says about its efficacy.
12mGLP-1 agonists have revolutionized metabolic health. Learn how these peptides work, their effects on metabolism, and how to use them strategically for body composition goals.
10mDevelop the skills to critically evaluate peptide research and distinguish solid science from marketing hype.
Also available at /blog for legacy links.